IMPLANON Drug Patent Profile

When do Implanon patents expire, and what generic alternatives are available?

Implanon is a drug marketed by Organon and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-seven countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Implanon

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 28, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IMPLANON

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	26
Patent Applications:	2,304
DailyMed Link:	IMPLANON at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IMPLANON

Constraining patent/regulatory exclusivity:

8,722,037

NDA:

021529

Dosage:

IMPLANT;IMPLANTATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IMPLANON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mata Poli de Arajo	EARLY_PHASE1
Organon	EARLY_PHASE1
Kenya Medical Research Institute	Phase 4

See all IMPLANON clinical trials

Pharmacology for IMPLANON

Drug Class

Progestin

US Patents and Regulatory Information for IMPLANON

IMPLANON is protected by one US patents.

This potential generic entry date is based on patent 8,722,037.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006		DISCN	No	No	9,757,552		Y

Expired US Patents for IMPLANON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006	4,957,119
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006	5,150,718

International Patents for IMPLANON

When does loss-of-exclusivity occur for IMPLANON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Egypt

Latvia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMPLANON around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	101086619
Ireland	882118
Russian Federation	2361628	АППЛИКАТОР ДЛЯ ВВЕДЕНИЯ ИМПЛАНТАТА (APPLICATOR FOR IMPLANT INTRODUCTION)
New Zealand	556491	Applicator for inserting an implant
Taiwan	200640518	Applicator for inserting an implant
Norway	20073748

Supplementary Protection Certificates for IMPLANON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0303306	SPC/GB99/044	United Kingdom		PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
0303306	29/1999	Austria		PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825
0303306	C980027	Netherlands		PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
0303306	099C0041	Belgium		PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825

Market Dynamics and Financial Trajectory for IMPLANON

Last updated: January 8, 2026

Executive Summary

IMPLANON, a biodegradable, subdermal contraceptive implant introduced by Merck & Co. (now MSD outside the U.S. and Canada), has established a significant footprint within hormonal contraceptive options since its approval in 2006. This article examines the evolving market landscape, key growth drivers, competitive positioning, regulatory influences, and financial projections guiding IMPLANON’s trajectory. A comprehensive analysis underscores its strategic importance amidst burgeoning global demand for long-acting reversible contraceptives (LARCs) and emerging market opportunities.

---

What Are the Market Demographics and Global Demand Drivers for IMPLANON?

Global Contraceptive Landscape and IMPLANON’s Market Share

Region	Estimated Women of Reproductive Age (15-49)	Contraceptive Prevalence (CPR)	% Using LARCs	Market Size (Units, 2022)	Key Drivers
North America	70 million	75%	20%	4.2 million	High awareness, insurance coverage, favorable policies
Europe	50 million	72%	22%	3.1 million	Advanced healthcare infrastructure
Asia-Pacific	400 million	64%	8%	15 million	Growing acceptance, female autonomy movements
Latin America	60 million	67%	15%	2.4 million	Government initiatives, increasing gender empowerment

Sources: Guttmacher Institute; WHO Data (2022).

Key Growth Drivers

1. Demand for Long-Acting Reversible Contraception (LARC)
   • LARCs constitute approximately 20% of contraceptive use globally, with an upward trend anticipated at 7% CAGR through 2030.[1]
2. Rising Female Workforce Participation
   • Particularly in Asia and Latin America, increased employment correlates with preference for discreet, long-term contraception.
3. Policy and Reimbursement Reforms
   • Investment in family planning programs by WHO and national governments fosters adoption.
4. Improved Awareness and Education
   • Campaigns reducing stigma around LARCs boost acceptance.
5. Innovations and Novel Formulations
   • Next-generation implants with extended efficacy and minimal side effects enhance consumer appeal.

Competitive Positioning and Market Share

Product	Manufacturer	Release Year	Mode of Action	Duration	Market Share (2022)	Price Range ($)	Unique Attributes
IMPLANON	MSD	2006	Etonogestrel implant	3 years	40%	650-900	Reversible, discreet, biodegradeable
Nexplanon	MSD	2012	Etonogestrel implant	3 years	55%	700-1,200	Thinner, radiopaque
other LARCs	Various	-	Various	3-5 years	5%	variable	Differing efficacy profiles

Note: The global implant market is projected to grow at a CAGR of 6.8% from 2022-2030[2].

---

How Have Regulatory and Policy Factors Shaped IMPLANON’s Financial Trajectory?

Regulatory Milestones and Approvals

Date	Region	Regulatory Body	Approval Details	Market Impact
2006	U.S.	FDA	Approved as Implanon	Initiated U.S. market access; initial uptake moderate
2012	Worldwide	EMA	Rebranded Nexplanon	Enhanced global recognition and market penetration
2015	China	CFDA	Approved	Accelerated growth in APAC markets

Reimbursement Policies and Insurance Coverage

• In the U.S., Medicaid expanded coverage for LARCs in 2014, contributing to 25% YoY growth in implant implants.[3]
• European countries like the UK and Germany include Nexplanon in publicly funded programs.

Impact on Revenue Streams

Year	Global Revenue (USD millions)	Growth Rate	Key Influencers
2018	340	4%	Expanded access, new markets
2020	410	20.6%	Pandemic-driven increased demand for LARCs
2022	480	17%	Continued policy support, product expansion

(Values estimated from MSD financial reports)

---

What Are the Financial Projections and Market Opportunities for IMPLANON?

Revenue Forecasts

Year	Estimated Revenue (USD millions)	Assumptions
2023	520	+8% YOY driven by Asia-Pacific and Latin America expansion
2025	630	Post-pandemic rebound, policy shifts favoring LARCs
2030	950	CAGR of 10% from 2022 levels; increased penetration in emerging markets

Drivers of Revenue Growth

1. Emerging Market Expansion
   • Population demographics and evolving health policies position Asia-Pacific and Latin America as high-growth zones.
2. Product Innovation
   • Introduction of next-generation implants with extended duration and improved tolerability.
3. Pricing Strategies
   • Tiered pricing models to improve affordability in low-income regions.
4. Partnerships & Distribution
   • Collaborations with government agencies and NGOs bolster outreach.

Potential Risks and Challenges

• Regulatory Delays or Restrictions
• Competition from New Contraceptive Technologies
• Pricing Pressures and Reimbursement Limitations
• Safety and Side Effect Profile Concerns

Competitive Landscape and Investment Outlook

Key Competitors	Strengths	Market Share	Strategic Moves (2022-2025)
MSD Nexplanon	Established global footprint, patented formulation	55%	Product line extensions & digital health integration
Bayer Implanon NXT	Extended Duration, Radio-opaque	25%	New markets in Africa & Southeast Asia
Local Generic Providers	Lower price points	10-15%	Price competition, localization strategies

---

How Will Market and Technological Trends Influence IMPLANON’s Future?

Market Trends

• Shifts Toward Integrated Family Planning Services
• Policy Advocacy for Gender Equality and Family Planning
• Digital Health Adoption for Patient Monitoring

Technological Innovations

• Biodegradable Implants – reducing environmental footprints
• Extended Duration Implants – up to 5 years
• Smart Implants – incorporating biosensors to track efficacy and side effects

Regulatory Outlook

• US FDA and EMA are likely to endorse newer, longer-acting biodegradable implants.
• Emerging markets may require local clinical data for approval, affecting timelines.

---

What Are the Critical Competitive Factors and Strategic Considerations?

Factor	Description	Implication for IMPLANON
Efficacy & Safety	Demonstrated in clinical trials	Continuous R&D to sustain confidence
Cost & Affordability	Price sensitivity in emerging markets	Tiered pricing & volume-driven models
Ease of Use & Discretion	User experience	Product design enhancements
Regulatory Access	Timely approvals	Proactive regulatory engagement
Distribution & Accessibility	Reach to underserved populations	Strengthening partnerships

---

Key Takeaways

• The global contraceptive market, especially LARCs, is poised for sustained growth at a CAGR of approximately 6-8% through 2030.
• IMPLANON has maintained a strong market position due to its efficacy, safety profile, and brand recognition, complemented by regulatory approvals in key markets.
• Emerging markets present significant expansion opportunities, driven by demographic shifts, policy support, and increasing awareness.
• Continuous innovation, including longer duration and eco-friendly formulations, will be critical in maintaining competitive advantage.
• Regulatory landscape, reimbursement policies, and socio-cultural factors remain pivotal in shaping future revenue streams.

---

FAQs

1. What are the main advantages of IMPLANON over other contraceptive methods?

IMPLANON offers a long-term, reversible contraceptive solution with minimal maintenance, high efficacy (>99%), and discreet administration, making it especially attractive for women seeking reliable, hassle-free contraception.

2. What are the current challenges facing IMPLANON's market growth?

Challenges include regulatory delays, competition from newer implant technologies, concerns over side effects like irregular bleeding, and affordability issues in low-income regions.

3. How does IMPLANON compare to hormonal IUDs?

While both are LARCs, IMPLANON (implant) provides three years of efficacy compared to hormonal IUDs' 3-7 years (depending on type). Implants are typically more incision-oriented and may present different side effect profiles.

4. What are the future product development directions for IMPLANON?

Innovations focus on longer-lasting (up to 5 years), biodegradable implants, integrating biosensors for real-time efficacy monitoring, and reducing side effects to enhance user experience.

5. How will global health policies influence IMPLANON's future?

Increased emphasis on family planning, reproductive health, and gender equality drives demand for effective, accessible contraceptive solutions like IMPLANON. Policy support in emerging markets can accelerate adoption, while regulatory harmonization expedites approvals.

---

References

1. Guttmacher Institute, “Global Contraceptive Use Trends,” 2022.
2. Market Research Future, “Global Contraceptive Implants Market Analysis,” 2022.
3. MSD Annual Report, 2022.
4. WHO Family Planning Data, 2022.

---

Disclaimer: All projections and analyses are based on available data as of 2023; actual market dynamics may vary due to unforeseen regulatory, technological, or socio-economic factors.